We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Stay Ahead of the Game With Globus Medical (GMED) Q2 Earnings: Wall Street's Insights on Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Globus Medical (GMED - Free Report) will report quarterly earnings of $0.76 per share in its upcoming release, pointing to a year-over-year increase of 1.3%. It is anticipated that revenues will amount to $741.7 million, exhibiting an increase of 17.8% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Globus Medical metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Net Sales by Product Category- Enabling Technologies' at $37.43 million. The estimate suggests a change of +1.8% year over year.
The consensus estimate for 'Net Sales by Product Category- Musculoskeletal Solutions' stands at $679.67 million. The estimate indicates a year-over-year change of +14.6%.
It is projected by analysts that the 'Geographic Revenues- International' will reach $140.52 million. The estimate points to a change of +7.9% from the year-ago quarter.
The consensus among analysts is that 'Geographic Revenues- United States' will reach $586.71 million. The estimate suggests a change of +17.5% year over year.
Shares of Globus Medical have experienced a change of -5.2% in the past month compared to the +0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), GMED is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Stay Ahead of the Game With Globus Medical (GMED) Q2 Earnings: Wall Street's Insights on Key Metrics
Wall Street analysts forecast that Globus Medical (GMED - Free Report) will report quarterly earnings of $0.76 per share in its upcoming release, pointing to a year-over-year increase of 1.3%. It is anticipated that revenues will amount to $741.7 million, exhibiting an increase of 17.8% compared to the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
With that in mind, let's delve into the average projections of some Globus Medical metrics that are commonly tracked and projected by analysts on Wall Street.
The average prediction of analysts places 'Net Sales by Product Category- Enabling Technologies' at $37.43 million. The estimate suggests a change of +1.8% year over year.
The consensus estimate for 'Net Sales by Product Category- Musculoskeletal Solutions' stands at $679.67 million. The estimate indicates a year-over-year change of +14.6%.
It is projected by analysts that the 'Geographic Revenues- International' will reach $140.52 million. The estimate points to a change of +7.9% from the year-ago quarter.
The consensus among analysts is that 'Geographic Revenues- United States' will reach $586.71 million. The estimate suggests a change of +17.5% year over year.
View all Key Company Metrics for Globus Medical here>>>Shares of Globus Medical have experienced a change of -5.2% in the past month compared to the +0.5% move of the Zacks S&P 500 composite. With a Zacks Rank #4 (Sell), GMED is expected to underperform the overall market in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .